Alcon Laboratories, Inc.

Alcon Research, Ltd.

Alcon, Inc.

Alcon Manufacturing, Ltd.

Novartis Ag

Other

Alcon Pharmaceuticals Ltd.

Merlion Pharmaceuticals Pte. Ltd.

Masood A Chowhan

Bahram Asgharian

Huagang Chen

Wesley Wehsin Han

Ronald P Quintana

Nissanke L Dassanayake

Thierry Bilbault

Bor-Shyue Hong

Ruth A Rosenthal

Bhagwati P Kabra

David W Stroman

Malay Ghosh

L Wayne Schneider

Kenneth C Appell

Ernesto J Castillo

G Michael Wall

Onkar N Singh

Rajni Jani

Paul E Stach

Nayan N Desai

Laman L Alani

Hwang-Hsing Chen

Martin B Wax

Glenn D Stafford, Jr

David J Keith

Brent G Boudreaux

Mark J Bridle

Wesley Weshin Han

Danny O Helton

Bryan H Huynh

R Gregg Harris

Thomas C Hohman

Connie L Luthy

Nissanke Lakshman Dassanayake

The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.

Compositions and methods for treating ophthalmic, octic, or nasal infections

The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).

Pharmaceutical compositions with phosphonium antimicrobial agents

The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.

Carboxylvinyl polymer-containing nanoparticle suspensions

The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a suspension composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin free base or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.

Finafloxacin suspension compositions

The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in creating a desirable release profile of therapeutic agent.

Injectable aqueous ophthalmic composition and method of use therefor

Methods for treating otic infections

Carboxyvinyl polymer-containing nanoparticle suspensions

Disclosed is a pharmaceutical composition comprising (a) a bioerodible water insoluble polymer matrix comprising a polyester polymer, wherein the polymer matrix has a melting point of less than 60&#xb0; C. and (b) an active agent dispersed within the polymer matrix, wherein the composition is formulated to controllably release the active agent for a pre -determined period of time to a target site. Also disclosed are methods of treating a disease or condition with the disclosed compositions.

Water insoluble polymer matrix for drug delivery

Methods for treating ophthalmic, otic, or nasal infections

New polymeric quaternary ammonium compounds with vicinal hydroxyl groups are disclosed. These compounds are useful as disinfectants in contact lens care compositions and/or as preservatives in ophthalmic compositions. Compositions containing these compounds are also disclosed. These compositions are especially useful for disinfecting/cleaning contact lenses.

Polymeric quaternary ammonium compounds with vicinal hydroxy groups

Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.

Olopatadine formulations for topical nasal administration

The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being 'self-preserved'. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.

Self preserved aqueous pharmaceutical compositions

The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.

Self-preserved aqueous pharmaceutical compositions

Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.

Ophthalmic compositions containing a synergistic combination of two polymers

The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.

Growing community of inventors

Arlington, TX, United States of America

Masood A Chowhan